Axsome Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
28 août 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
08 août 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Interim analysis results from two Phase 3 trials and topline results from one Phase 2 trial of AXS-05 anticipated in 4Q 2018 Phase 3 trial of AXS-07 in acute migraine anticipated to start in 4Q 2018 ...
Axsome Therapeutics to Report Second Quarter 2018 Financial Results on August 8, 2018
01 août 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Wednesday, August 8, 2018 at 8:00 AM Eastern Time NEW YORK, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer’s Association International Conference
17 juil. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Initiates Phase 2 Trial of AXS-05 in Major Depressive Disorder
05 juin 2018 07h00 HE
|
Axsome Therapeutics, Inc.
First patient enrolled in the ASCEND study Trials in two mood disorders now underway with AXS-05 NEW YORK, June 05, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a...
Axsome Therapeutics to Present Data on AXS-05 at the 2018 American Society of Clinical Psychopharmacology Annual Meeting
29 mai 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, May 29, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Therapeutics to Present at the 2018 BIO International Convention
22 mai 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
08 mai 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric Association
03 mai 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
Axsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018
01 mai 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Tuesday, May 8, 2018 at 8:00 AM Eastern Time NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage...